A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner

Selina K. Sutton, Daniel R. Carter, Patrick Kim, Owen Tan, Greg M. Arndt, Xu Dong Zhang, Jonathan Baell, Benjamin D. Noll, Shudong Wang, Naresh Kumar, Grant A. McArthur, Belamy B. Cheung, Glenn M. Marshall

Research output: Contribution to journalArticle

Abstract

There is an urgent need for better therapeutic options for advanced melanoma patients, particularly those without the BRAFV600E/K mutation. In melanoma cells, loss of TRIM16 expression is a marker of cell migration and metastasis, while the BRAF inhibitor, vemurafenib, induces melanoma cell growth arrest in a TRIM16-dependent manner. Here we identify a novel small molecule compound which sensitized BRAF wild-type melanoma cells to vemurafenib. High throughput, cell-based, chemical library screening identified a compound (C012) which significantly reduced melanoma cell viability, with limited toxicity for normal human fibroblasts. When combined with the BRAFV600E/K inhibitor, vemurafenib, C012 synergistically increased vemurafenib potency in 5 BRAFWT and 4 out of 5 BRAFV600E human melanoma cell lines (Combination Index: CI < 1), and, dramatically reduced colony forming ability. In addition, this drug combination was significantly anti-tumorigenic in vivo in a melanoma xenograft mouse model. The combination of vemurafenib and C012 markedly increased expression of TRIM16 protein, and knockdown of TRIM16 significantly reduced the growth inhibitory effects of the vemurafenib and C012 combination. These findings suggest that the combination of C012 and vemurafenib may have therapeutic potential for the treatment of melanoma, and, that reactivation of TRIM16 may be an effective strategy for patients with this disease.

LanguageEnglish
Pages52166-52178
Number of pages13
JournalOncoTarget
Volume7
Issue number32
DOIs
StatePublished - 1 Aug 2016

Keywords

  • BRAF inhibitor
  • Melanoma
  • Novel compound
  • TRIM16
  • Vemurafenib

Cite this

Sutton, S. K., Carter, D. R., Kim, P., Tan, O., Arndt, G. M., Zhang, X. D., ... Marshall, G. M. (2016). A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. OncoTarget, 7(32), 52166-52178. DOI: 10.18632/oncotarget.10700
Sutton, Selina K. ; Carter, Daniel R. ; Kim, Patrick ; Tan, Owen ; Arndt, Greg M. ; Zhang, Xu Dong ; Baell, Jonathan ; Noll, Benjamin D. ; Wang, Shudong ; Kumar, Naresh ; McArthur, Grant A. ; Cheung, Belamy B. ; Marshall, Glenn M./ A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. In: OncoTarget. 2016 ; Vol. 7, No. 32. pp. 52166-52178
@article{a22701a590ff4505b4a797c04aa16ded,
title = "A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner",
abstract = "There is an urgent need for better therapeutic options for advanced melanoma patients, particularly those without the BRAFV600E/K mutation. In melanoma cells, loss of TRIM16 expression is a marker of cell migration and metastasis, while the BRAF inhibitor, vemurafenib, induces melanoma cell growth arrest in a TRIM16-dependent manner. Here we identify a novel small molecule compound which sensitized BRAF wild-type melanoma cells to vemurafenib. High throughput, cell-based, chemical library screening identified a compound (C012) which significantly reduced melanoma cell viability, with limited toxicity for normal human fibroblasts. When combined with the BRAFV600E/K inhibitor, vemurafenib, C012 synergistically increased vemurafenib potency in 5 BRAFWT and 4 out of 5 BRAFV600E human melanoma cell lines (Combination Index: CI < 1), and, dramatically reduced colony forming ability. In addition, this drug combination was significantly anti-tumorigenic in vivo in a melanoma xenograft mouse model. The combination of vemurafenib and C012 markedly increased expression of TRIM16 protein, and knockdown of TRIM16 significantly reduced the growth inhibitory effects of the vemurafenib and C012 combination. These findings suggest that the combination of C012 and vemurafenib may have therapeutic potential for the treatment of melanoma, and, that reactivation of TRIM16 may be an effective strategy for patients with this disease.",
keywords = "BRAF inhibitor, Melanoma, Novel compound, TRIM16, Vemurafenib",
author = "Sutton, {Selina K.} and Carter, {Daniel R.} and Patrick Kim and Owen Tan and Arndt, {Greg M.} and Zhang, {Xu Dong} and Jonathan Baell and Noll, {Benjamin D.} and Shudong Wang and Naresh Kumar and McArthur, {Grant A.} and Cheung, {Belamy B.} and Marshall, {Glenn M.}",
year = "2016",
month = "8",
day = "1",
doi = "10.18632/oncotarget.10700",
language = "English",
volume = "7",
pages = "52166--52178",
journal = "OncoTarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "32",

}

Sutton, SK, Carter, DR, Kim, P, Tan, O, Arndt, GM, Zhang, XD, Baell, J, Noll, BD, Wang, S, Kumar, N, McArthur, GA, Cheung, BB & Marshall, GM 2016, 'A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner' OncoTarget, vol 7, no. 32, pp. 52166-52178. DOI: 10.18632/oncotarget.10700

A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. / Sutton, Selina K.; Carter, Daniel R.; Kim, Patrick; Tan, Owen; Arndt, Greg M.; Zhang, Xu Dong; Baell, Jonathan; Noll, Benjamin D.; Wang, Shudong; Kumar, Naresh; McArthur, Grant A.; Cheung, Belamy B.; Marshall, Glenn M.

In: OncoTarget, Vol. 7, No. 32, 01.08.2016, p. 52166-52178.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner

AU - Sutton,Selina K.

AU - Carter,Daniel R.

AU - Kim,Patrick

AU - Tan,Owen

AU - Arndt,Greg M.

AU - Zhang,Xu Dong

AU - Baell,Jonathan

AU - Noll,Benjamin D.

AU - Wang,Shudong

AU - Kumar,Naresh

AU - McArthur,Grant A.

AU - Cheung,Belamy B.

AU - Marshall,Glenn M.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - There is an urgent need for better therapeutic options for advanced melanoma patients, particularly those without the BRAFV600E/K mutation. In melanoma cells, loss of TRIM16 expression is a marker of cell migration and metastasis, while the BRAF inhibitor, vemurafenib, induces melanoma cell growth arrest in a TRIM16-dependent manner. Here we identify a novel small molecule compound which sensitized BRAF wild-type melanoma cells to vemurafenib. High throughput, cell-based, chemical library screening identified a compound (C012) which significantly reduced melanoma cell viability, with limited toxicity for normal human fibroblasts. When combined with the BRAFV600E/K inhibitor, vemurafenib, C012 synergistically increased vemurafenib potency in 5 BRAFWT and 4 out of 5 BRAFV600E human melanoma cell lines (Combination Index: CI < 1), and, dramatically reduced colony forming ability. In addition, this drug combination was significantly anti-tumorigenic in vivo in a melanoma xenograft mouse model. The combination of vemurafenib and C012 markedly increased expression of TRIM16 protein, and knockdown of TRIM16 significantly reduced the growth inhibitory effects of the vemurafenib and C012 combination. These findings suggest that the combination of C012 and vemurafenib may have therapeutic potential for the treatment of melanoma, and, that reactivation of TRIM16 may be an effective strategy for patients with this disease.

AB - There is an urgent need for better therapeutic options for advanced melanoma patients, particularly those without the BRAFV600E/K mutation. In melanoma cells, loss of TRIM16 expression is a marker of cell migration and metastasis, while the BRAF inhibitor, vemurafenib, induces melanoma cell growth arrest in a TRIM16-dependent manner. Here we identify a novel small molecule compound which sensitized BRAF wild-type melanoma cells to vemurafenib. High throughput, cell-based, chemical library screening identified a compound (C012) which significantly reduced melanoma cell viability, with limited toxicity for normal human fibroblasts. When combined with the BRAFV600E/K inhibitor, vemurafenib, C012 synergistically increased vemurafenib potency in 5 BRAFWT and 4 out of 5 BRAFV600E human melanoma cell lines (Combination Index: CI < 1), and, dramatically reduced colony forming ability. In addition, this drug combination was significantly anti-tumorigenic in vivo in a melanoma xenograft mouse model. The combination of vemurafenib and C012 markedly increased expression of TRIM16 protein, and knockdown of TRIM16 significantly reduced the growth inhibitory effects of the vemurafenib and C012 combination. These findings suggest that the combination of C012 and vemurafenib may have therapeutic potential for the treatment of melanoma, and, that reactivation of TRIM16 may be an effective strategy for patients with this disease.

KW - BRAF inhibitor

KW - Melanoma

KW - Novel compound

KW - TRIM16

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=84982286483&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10700

DO - 10.18632/oncotarget.10700

M3 - Article

VL - 7

SP - 52166

EP - 52178

JO - OncoTarget

T2 - OncoTarget

JF - OncoTarget

SN - 1949-2553

IS - 32

ER -

Sutton SK, Carter DR, Kim P, Tan O, Arndt GM, Zhang XD et al. A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. OncoTarget. 2016 Aug 1;7(32):52166-52178. Available from, DOI: 10.18632/oncotarget.10700